What criteria do you use when considering treating the pelvic nodes in a salvage prostatectomy case?

Perhaps I am biased because I have conducted research in this area, but I believe this is one of the more intriguing questions in our field. Particularly, given how many men are referred for post-prostatectomy salvage radiotherapy for a rising PSA. I had enthusiastically enrolled patients onto the RTOG 0534 clinical trial, and like many, had also been patiently awaiting the initial results that were just presented at ASTRO 2018.

Alan Pollack's presentation confirmed what had already been seen in ...

I'd appreciate more data on this question too to help refine decision-making.

RTOG 0534 (Pollack et al., PMID 35569466) reported reduced 5-year biochemical failure, regional failure, distant metastasis, time to second androgen deprivation, and castrate resistant disease with elective node irradiation (ENI) plus short term androgen deprivation vs prostate bed alone or prostate bed and short term ADT. Supplementary Table S8 lists cumulative incidence primary and secondary outcomes to appreciate ap...